Stenting in benign oesophageal stricture
ISRCTN | ISRCTN05817794 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN05817794 |
Secondary identifying numbers | PB-PG-1208-17025 |
- Submission date
- 28/07/2010
- Registration date
- 26/08/2010
- Last edited
- 05/02/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English Summary
Not provided at time of registration
Contact information
Dr Anjan Dhar
Scientific
Scientific
Consultant Gastroenterologist
Department of Gastroenterology
Darlington Memorial and Bishop Auckland Hospitals
County Durham and Darlington NHS Foundation Trust
Cockton Hill Road
Bishop Auckland
DL14 6AD
United Kingdom
Phone | +44 (0)1388 455170 |
---|---|
anjan.dhar@cddft.nhs.uk |
Study information
Study design | Two-arm 1:1 prospective randomised controlled clinical trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | Biodegradable stent in benign oesophageal stricture compared to standard balloon dilatation treatment: a two-arm 1:1 randomised clinical trial |
Study acronym | BESST |
Study hypothesis | This pilot study addresses the potential effectiveness and cost-effectiveness of biodegradable stent placement in patients with benign oesophageal stricture. The study will determine the feasibility and utility of a randomised controlled trial design comparing biodegradable oesophageal stent or standard dilatation in symptomatic adult patients diagnosed with refractory oesophageal stricture. The primary endpoint will be ability to swallow, assessed by a five point dysphagia score (assessed by a blinded observer at baseline, 3, 6 and 12 months). Secondary end points will include the acceptability of procedures and overall care to patients, the number of repeat endoscopic procedures (therapeutic and diagnostic), adverse events (including hospital admissions), quality of life assessed physically using surrogate markers such as weight and serum albumin and by generic quality of life assessment (EuroQol EQ-5D) and economic analysis. Economic analysis will be conducted from an NHS perspective. Stochastic cost-effectiveness analysis will use patient-level, within-trial (1 year) cost and quality-adjusted life-year (QALY) data. Modelling using probabilistic methods will explore extrapolations of benefits beyond one-year. The summative aim is to show the potential value of a new treatment option which may improve the quality of life for patients and be a cost-effective alternative for the NHS. The proposed pilot study is an essential step to establish the need for a larger trial and to provide the necessary evidence base to inform patients and the NHS. |
Ethics approval(s) | Not provided at time of registration |
Condition | Benign oesophageal strictures |
Intervention | The study will involve endoscopic interventions of balloon dilatation with or without fluroscopy in one (control) arm and placement of a biodegradable stent in the other arm. The treatment in each arm is a one time procedure. Patients will be followed up for a period of 12 months after the endoscopic intervention in each arm. |
Intervention type | Other |
Primary outcome measure | The average dysphagia (swallowing) score response over 12 months |
Secondary outcome measures | 1. Acceptibility of procedures to patients 2. Number of repeat endoscopic procedures 3. Frequency of refractory disease 4. Adverse events 5. Quality of life assessed physically using surrogate markers of weight, serum albumin and by generic quality of life assessment (EuroQol EQ-5D) 6. Patient level, NHS perspective, cost and cost-effectiveness analysis Measured at 3, 6 and 12 months following the endoscopic intervention in both arms |
Overall study start date | 01/11/2010 |
Overall study end date | 31/10/2013 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | 50 |
Participant inclusion criteria | 1. Signed written informed consent 2. Confirmed diagnosis of benign oesophageal stricture 3. Adults aged between 18 and 75 years, either sex 4. At least one previous oesophageal dilatation for management of their benign oesophageal stricture |
Participant exclusion criteria | 1. Patients who do not fulfil the inclusion criteria 2. Patients with high strictures 3. Pregnant patients 4. Receiving anti-coagulants 5. Diagnosis or oesophageal cancer 6. Diagnosis of a terminal disease 7. A history of any medical illness which, in the Investigator's discretion would inhibit the patient's participation 8. Women of child bearing potential who refuse to use adequate contraception for three months post-intervention |
Recruitment start date | 01/11/2010 |
Recruitment end date | 31/10/2013 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Darlington Memorial and Bishop Auckland Hospitals
Department of Gastroenterology
Bishop Auckland
DL14 6AD
United Kingdom
Bishop Auckland
DL14 6AD
United Kingdom
Sponsor information
County Durham and Darlington NHS Foundation Trust (UK)
Hospital/treatment centre
Hospital/treatment centre
c/o Dr Yan Yiannakou
Director of Research & Development
Research & Development Directorate
County Durham & Darlington NHS Foundation Trust
Pierremont Unit
Darlington Memorial Hospital
Hollyhurst Road
Darlington
DL3 6HX
England
United Kingdom
Phone | +44 (0)1325 743 737 |
---|---|
yan.yiannakou@cddft.nhs.uk | |
Website | http://www.cddft.nhs.uk |
https://ror.org/03vamsh08 |
Funders
Funder type
Government
National Institute for Health Research (NIHR) (UK) - Research for Patient Benefit (RfPB) programme (ref: PB-PG-1208-17025)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 28/12/2014 | Yes | No |
Editorial Notes
05/02/2016: Publication reference added